• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A method for the selective methylation of the hydroxy group at the 6-position of erythromycin A derivatives which comprises reacting a compound represented by the formula R-X (wherein R is a 2-alkenyl group, a benzyl group or a substituted benzyl group, and X is a halogen atom), reacting the resulting quaternary salt compound with a methylating agent, and then eliminating R groups of the resulting compound to give 6-0-methylerythromycin A 9-oxime, is disclosed.
    公开号:SU1468426A3
    申请号:SU864027110
    申请日:1986-03-17
    公开日:1989-03-23
    发明作者:Моримото Сигео；Адати Такаси；Асака Тосифуми；Касимура Масато；Ватанабе Есиаки；Сота Каору
    申请人:Таисе Фармасьютикал Ко.,Лтд (Фирма)；
    IPC主号:
    专利说明:

    triethylammonium formate in aqueous dioxane.
    Example 1. 1. To a solution of 10 (0.0134 mol) erythromycin 9-oxime in 100 ml of a mixture of dimethyl sulfoxide and tetrahydrofuran 1: 1 (by volume) were added 4.6 ml (0.053 mol) of allylbromide, and then the mixture stir at room temperature for 2 hours. After cooling the reaction solution with ice, 1.41 g (0.03 mol) (50%) of sodium hydride is added and the mixture is stirred at room temperature for 2.5 hours. Op after addition of 150 m of water, extracted with 2x150 ml of ethyl acetate. The solvent is evaporated, the result is a crude product, which is then subjected to crystallization from a mixture of chloroform - hexane, resulting in a gain of 10.79 g (85%) of 9- (0-allyl) -oxime bromide 2-0.3 -N-diallylyrythromycin .
    2. In 42 ml of a mixture of dimethyl sulfoxide with a tetrahydrofuran 1: 1 (by volume) 10.5 g (0.011 mol) of the compound obtained according to item 1 are dissolved, and then 2.06 ml (0.033 mol) of methyl iodide and 948 mg (0.014 mol) are added. mol) (85%) of potassium hydroxide powder, while cooling the ice with ice. After stirring for
    2 hours, the reaction solution is poured into 150 ml of water and extracted with 2x150 ml of ethyl acetate. The ethyl acetate layer was washed once with 150 ml of a saturated aqueous solution of sodium chloride, and the solvent was evaporated under reduced pressure. The resulting technical product is mixed with 40 ml of chloroform and filtered, and the filtrate is concentrated and a result of 12.72 g of a crude 6-0-methyl derivative is obtained.
    3. In a mixture of 64 ml of dioxane and 10 ml of water dissolve 12.72 g of the compound obtained in paragraph 2 and add 636 mg (0.003 mol) of palladium acetate and 3.0 g (0.011 mol) of triphenylphosphine
    and 16 ml of triethylammonium formate. After boiling with stirring for 2 h, the reaction solution is cooled, poured into 200 ml of ether and then washed once with 200 ml of water and once with 100 ml of water, respectively. The aqueous layers are combined and the pH of the solution is set to about 9 by the addition of carbonate.
    l jc 20
    25 jq
    35
    40
    45
    five
    rub while cooling with ice. The solution is extracted with 2x300 ml of ether, and then the ether layer is washed with 400 ml of saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate. The solvent is evaporated, the resulting technical product is purified using a chromatographic column on silica gel (eluent: chloroform: methanol 9: 1) and then crystallized from ethanol-petroleum ether to give 4.983 g (59.6%) 9-oxime 6-0-methylerythromyrna A.
    M.p. 248-251 ° C, melts at 169-171 ° C, hardens again at 180-185 ° C and again melts at 248-25 ° C.
    IR spectrum V Or: 3400, 1730, 1625.
     H-NMR (400 MHz, CDCl).
    .d .: 2.29 f6H, singlet, “(CHj); 3.11 (SN, singlet, b-och); 3.33 (SA, singlet, 3-OSIz).
     C-NMR (50.3 MHz, CDClj).
    Gm.d .: 170.1 (C-9); 78.8 (C-6); 51.2 (C-OSiZ); 49.5 (Sz-OCHs), 40.4 GK (25.4 (C-8); 20.0 ().
    Mass Spectrum (S IM S) m / e 763 (MNH.
    Calculated,%: C 59.82; H 9.29; N 3.67.
    Found,%: C 59.79; H 9.10, N 3.70.
    ,,.
    Example 2. 1. To a solution of 5 g (0.0067 mol) of erythromycin A 9-oxime in 10 ml of tetrahydrofuran was added 1.2 ml (0.01 mol) of benzyl bromide and the mixture was boiled for 5.5 h. 10 ml of dimethyl sulfoxide, then 2 ml (0.017 mol) of benzyl bromide and 1.01 g (0.015 mol) (85%) of potassium hydroxide powder are added to the ice-cooled reaction solution with simultaneous cooling with ice. After stirring at room temperature for 4 hours, the reaction solution is poured into 100 ml of water and extracted with 2x100 ml of ethyl acetate. The solvent is evaporated and get a technical product, which is then subjected to recrystallization from a mixture of ethanol and n-hexane, resulting in a gain of 5.02 g (74.5%) 9- (0-benzyl) -oxime bromide 2-0.3 -N - - dibenzylerythromycin A.
    2. In 13.2 ml of a mixture of dimethylsulfoxid 1: 1 (by volume) with tetrahydrofuran, 3.3 g (0.033 mol) of the compound obtained in paragraph 1 are dissolved, and then 0.57 ml (0.009 mol) of methyl iodide and 0.26 g (0.004 mol) (85%) of potassium hydroxide powder, while cooling with ice. After stirring for 2 hours, the reaction solution is poured into 100 ml of water and extracted with 2x100 ml of ethyl acetate. The solvent is evaporated, and then a crude product is obtained which is recrystallized from a mixture of ethyl acetate and cyclohexane, to obtain 2.936 g of the 6-0-methyl derivative.
    3, To a solution of 2.93 g of the compound obtained in 2, in 25 ml of methanol, 2.3 g (10%) of palbenzyl bromide was added and the mixture was stirred at room temperature for 1.5 hours. 0.737 g (0.015 mol) of 50% sodium hydride and the mixture is stirred at room temperature for 2 hours. The reaction solution, after adding 150 ml of water, is extracted with 10 2 x 150 ml of ethyl acetate. Thinner evaporated, resulting in a technical product, which is recrystallized from a mixture of chloroform and n-hexane and as a result of 15 get 6,34 g (94,5%) 9- (0-benzyl) oxime bromide. 2-O, 3 -Y-dibeneyl-erythromycin A.
    2. In 20 ml of a mixture of dimethyl sulfoxide with tetrahydrofuran 1: 1 (by volume) 20, 5 g (0.005 mol) of the compound obtained above under point 1 are dissolved, and then O, 85 ml (0.014 mol) of methyl iodide and 0, 39 g (0.006 mol) of potassium oxide hydrate (85%) correspond to carbon (humidity 52.6%). While cooling simultaneously with 0.305 g (0.005 mol) of ammonium formate and 1.84 ml (0.05 mol) (99%) of formic acid, the mixture is stirred for 3 hours. The catalyst is filtered and washed with methanol. The filtrate and the washing liquid are combined and concentrated under reduced pressure.
    In the OSTALD thus obtained. After stirring for 2 hours, the reaction solution is poured into 100 ml of water and extracted with 2x1100 ml of ethyl acetate. The solvent is evaporated, 30 and the residue is taken up with 30 ml of petroleum ether and dried, yielding 5.47 g of b-O-methyl derivative.
    3. In 50 ml of N, N-dimethylformamide
     60 ml of an aqueous solution is added. 5 Dissolve 5 g of the compound, obtained
    sodium carbonate and the mixture is extracted with 2x70 MP of ethyl acetate. The organic layer is washed with 140 ml of saturated aqueous sodium chloride solution, and then dried over anhydrous magnesium sulfate. The solvent is evaporated under reduced pressure and, thus, 1.75 g of technical product is obtained, which is then recrystallized from a mixture of ethanol and petroleum ether and 1.17 g (47.43%) of 9-oxime-6 are obtained. -0-methylethromycin A.
    The physical characteristics, such as melting point, IR spectrum, H-SHR spectrum, C-H11R-спект spectrum and mass spectrum of this compound, are identical to the corresponding characteristics for the compound obtained in Example 1.3.
    Example 3. 1. In 50 ml of a mixture of dimethyl sulfoxide and tetrahydrofuran 1: 1 (by volume) 5 g (0.0067 mol) of 9-oxime erythromycin A are dissolved, 3.18 ml (0.027 mol) are added
    Paragraph 2, then 1 g (10%) of palladium on carbon (humidity 52.6%) and 5.63 g (0.09 mol) of ammonium formate are added. After stirring at a temperature of 50 ° C for 3 hours, the reaction mixture is cooled and the catalyst is filtered off and washed with a small amount of methanol. The filtrate and the washings were combined, poured into 130 ml of water and extracted with 2x130 ml of ethyl acetate. The organic layer is washed once with 250 ml of a saturated aqueous solution of sodium chloride and in a concentration of 50 RUT. The residue is dissolved in 50 ml of methanol, then 4 g (10%) of palladium on carbon (moisture content 52.6%), 0.52 g (0.008 mol) of ammonium formate, and 3.15 ml (0.08 mol a) 55 ml of acid, and then the mixture is stirred at 3 hours. After cooling the mixture, the catalyst is filtered off and washed with methanol. Filtrate and flush
    1468.426
    benzyl bromide and the mixture is stirred at room temperature for 1.5 hours. 0.737 g (0.015 mol) of 50% sodium hydride is added to the reaction solution and the mixture is stirred at room temperature for 2 hours. The reaction solution after the addition of 150 ml water is extracted with 0 2x150 ml of ethyl acetate. Thinner evaporated, resulting in a technical product, which is recrystallized from a mixture of chloroform and n-hexane and in the result 5 get 6,34 g (94,5%) 9- (0-benzyl) oxime bromide. 2-O, 3 -Y-dibeneyl-erythromycin A.
    2. In 20 ml of a mixture of dimethyl sulfoxide with tetrahydrofuran 1: 1 (by volume) 0, 5 g (0.005 mol) of the compound obtained above under point 1 are dissolved, and then O, 85 ml (0.014 mol) of methyl iodide and 0, 39 g (0.006 mol) of potassium oxide hydrate (85%), respectively, while cooling
    by ice. After stirring for 2 hours, the reaction solution is poured into 100 ml of water and extracted with 2x1100 ml of ethyl acetate. The solvent is evaporated, 30 and the residue is taken up with 30 ml of petroleum ether and dried, yielding 5.47 g of b-O-methyl derivative.
    3. In 50 ml of N, N-dimethylformamide
    5 Dissolve 5 g of the compound, obtained. 5 Dissolve 5 g of the compound obtained.
    Paragraph 2, then 1 g (10%) of palladium on carbon (humidity 52.6%) and 5.63 g (0.09 mol) of ammonium formate are added. After stirring at a temperature of 50 ° C for 3 hours, the reaction mixture is cooled and the catalyst is filtered off and washed with a small amount of methanol. The filtrate and the washings were combined, poured into 130 ml of water and extracted with 2x130 ml of ethyl acetate. The organic layer is washed once with 250 ml of a saturated aqueous solution of sodium chloride and in a concentration of 50 RUT. The residue is dissolved in 50 ml of methanol, then 4 g (10%) of palladium on carbon (moisture content 52.6%), 0.52 g (0.008 mol) of ammonium formate, and 3.15 ml (0.08 mol a) 55 ml of acid, and then the mixture is stirred at 3 hours. After cooling the mixture, the catalyst is filtered off and washed with methanol. Filtrate and flush
    the liquid is combined and concentrated under reduced pressure. The resulting residue after adding 100 ml of an aqueous solution of sodium carbonate is extracted with 2x100 mp of ethyl acetate. The organic layer is washed with 200 ml of a saturated aqueous solution of sodium chloride and dried over anhydrous magnesium sulphate. The rastor is evaporated under reduced pressure and thus 3.26 g of the cf product are obtained, which is then subjected to crystallization from an ethanol-petroleum ether mixture, as a result of which 2.07 g (60.5%) of 9-oxime 6 are obtained. -0-methylethromycin A.
    The physical characteristics are identical to the same physical characteristics of the compound prepared in Example 1.3.
    权利要求:
    Claims (1)
    [1]
    Example 4. 3-0-methyl erythromycin Au, 9g of oxime, 3.27 g of sodium hydroxide is dissolved in a mixture of 30 ml of ethanol and 30 ml of water and the solution is refluxed with stirring for 6 hours. The solution is cooled to room temperature, 60 ml of water and the pH of the solution is provided at a level greater than 10 with a saturated aqueous solution of sodium carbonate. The precipitate which forms in this way is collected by filtration, washed thoroughly with water and subjected to recrystallization from ethanol, yielding 2.01 g of 6-0-methylerythromycin A, m.p. 223-225 C.,. Formula image shadows
    The method of obtaining the 9-oxime 6-0-methyl-erythromycin A of the formula
    "3.Shz
    about
    SNS
    he
    Compiled by
    characterized in that erythromycin A 9-oxime is reacted with a halogen derivative of the general formula
    R - X
    where R is allyl or benzyl
    Group; X - bromine,
    3 in the presence of potassium hydroxide or sodium hydride at a molar ratio of reagents: 1: 4: 2.24-2.3, respectively, in a mixture of dimethyl sulfoxide and tetrahydrofuran at a temperature from to room temperature, the resulting quaternary derivative of the general formula
    sn.
    Ron
    where R and X have the indicated meanings, are reacted with methyl iodide in the presence of potassium hydroxide, the reagents are used in a molar ratio of 1: 2.7: 3: 1.2-1.3, respectively, the interaction is carried out in a dimethyl sulfon mixture - foxid and tetrahydrofuran, followed by hydrogenolysis in the presence of palladium on carbon, ammonium formate, formic acid in methanol or in the presence of palladium acetate, triphenylphosphine, triethylammonium formate in aqueous dioxane.
    Priority by signs: 18.03.85 for all features of the claims, except R — an allyl group;
    21.09.85 with R - allyl group
    Editor A. Kozoriz
    Tehred L. Serdyukova
    Order 1220/59
    Circulation 339
    VNIIPI State Committee for Inventions and Discoveries at the State Committee on Science and Technology of the USSR 113035, Moscow, Zh-35, Raushsk nab. 4/5
    Corrector L, Patay
    Subscription
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1468426A3|1989-03-23|Method of producing 9-oxime 6-0-methylerythromycin a
    EP0115248B1|1990-02-28|Substituted 5h-pyrimido|indoles
    DE69822871T2|2005-03-03|CHEMICAL SYNTHESIS OF 6-O-ALKYL ERYTHROMYCIN A
    Schroeder et al.1967|Lincomycin. III. Structure and stereochemistry of the carbohydrate moiety
    SU967275A3|1982-10-15|Process for producing 4-phenylpiperidines or their salts
    EP0080819A1|1983-06-08|11-0-Alkylerythromycin A derivatives
    US3985811A|1976-10-12|5-Chloro-2-hydroxymethyl benzhydrol
    US3780070A|1973-12-18|4-azido-17alpha-alkinyl-4-gonen-17beta-ol-3-ones and method for their preparation
    Weber et al.1986|Methyl 2, 3-dideoxy-3-nitro-D-erythro-pentofuranoside, isomers and derivatives
    EP0190534A1|1986-08-13|Process for the preparation of ergoline derivatives
    US4002609A|1977-01-11|Sucrose derivatives
    Ball et al.1959|5, 6-DIDEOXY-l-ARABINO-HEXOSE |
    TW296381B|1997-01-21|
    US3984461A|1976-10-05|3-0-|-11-oxo-18-beta-olean-12-en-30-oic acid
    SU922108A1|1982-04-23|Process for producing derivatives of 6-methyl-8-beta-hydrazinomethylergolin or their salts
    US4730049A|1988-03-08|Process for preparing 5-|-4,5,6,7-tetrahydrothieno |pyridine
    US5410038A|1995-04-25|method of preparing D-altrose
    US3833667A|1974-09-03|Process for the preparation of 1,2-di-|-ethanol
    US3183247A|1965-05-11|Galactonolactones, derivatives thereof, and process for their preparation
    KR940004074B1|1994-05-11|Production of 4'-o-tetrahydropyranyladriamycin b.
    IL36330A|1974-09-10|The preparation of acetyl derivatives of steroidal cardiac active glycosides
    US4117245A|1978-09-26|Process for the production of norpatchoulenol
    KR910005898B1|1991-08-06|Method for preparaing 6-o-methyl-2'-o,n-bis|-n-demethylery thromycin a
    US4055594A|1977-10-25|Intermediates useful for the production of norpatchoulenol
    DE3312735A1|1983-10-20|NEW 23-DEMYCINOSYLDESMYCOSINE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
    同族专利:
    公开号 | 公开日
    FI80708C|1990-07-10|
    KR920002142B1|1992-03-12|
    ES553048A0|1987-11-16|
    DE3661420D1|1989-01-19|
    EP0195960B1|1988-12-14|
    KR860007281A|1986-10-10|
    AU5411086A|1986-09-25|
    FI861072A|1986-09-19|
    DK172583B1|1999-02-08|
    ES8800689A1|1987-11-16|
    JPH0676432B2|1994-09-28|
    PT82210A|1986-04-01|
    CA1234806A|1988-04-05|
    DK121586A|1986-09-19|
    FI80708B|1990-03-30|
    AU574265B2|1988-06-30|
    US4670549A|1987-06-02|
    EP0195960A1|1986-10-01|
    JPS62149695A|1987-07-03|
    FI861072A0|1986-03-14|
    PT82210B|1988-07-29|
    DK121586D0|1986-03-17|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3923784A|1973-09-10|1975-12-02|Hoffmann La Roche|Erythromycin a derivatives|
    US4264765A|1980-02-20|1981-04-28|Abbott Laboratories|Salts of erythromycin A esters|
    US4331803A|1980-06-04|1982-05-25|Taisho Pharmaceutical Co., Ltd.|Novel erythromycin compounds|
    JPH0443076B2|1983-12-02|1992-07-15|Taisho Pharma Co Ltd|
    JPH053475B2|1984-04-06|1993-01-14|Taisho Pharma Co Ltd|
    JPH053476B2|1984-10-26|1993-01-14|Taisho Pharma Co Ltd|JPH053476B2|1984-10-26|1993-01-14|Taisho Pharma Co Ltd|
    JPS63107994A|1986-05-02|1988-05-12|Taisho Pharmaceut Co Ltd|Erythromycin derivative|
    EP0260938B1|1986-09-18|1992-12-09|Taisho Pharmaceutical Co. Ltd|Erythromycin a derivatives and method for preparing the same|
    KR960000434B1|1986-12-17|1996-01-06|다이쇼 세이야꾸 가부시끼가이샤|Eryhromycin a derivatives and process of method for the same|
    US5075289A|1988-06-07|1991-12-24|Abbott Laboratories|9-r-azacyclic erythromycin antibiotics|
    US5302705A|1989-10-07|1994-04-12|Taisho Pharmaceutical Co., Ltd.|6-O-methylerythromycin a oxime derivatives|
    FR2669337B1|1990-11-21|1995-03-24|Roussel Uclaf|NOVEL DESCLADINOSYL DERIVATIVES OF ERYTHROMYCIN, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS.|
    IL99995A|1990-11-21|1997-11-20|Roussel Uclaf|Erythromycin derivatives, their preparation and pharmaceutical compositions containing them|
    FR2677025B1|1991-05-27|1995-04-07|Roussel Uclaf|NOVEL DESCLADINOSYL DERIVATIVES OF ERYTHROMYCIN, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS.|
    FR2680790B1|1991-08-29|1996-10-31|Roussel Uclaf|NOVEL DESCLADINOSYL DERIVATIVES OF ERYTHROMYCIN, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS.|
    US5872229A|1995-11-21|1999-02-16|Abbott Laboratories|Process for 6-O-alkylation of erythromycin derivatives|
    US5719272A|1996-04-02|1998-02-17|Abbott Laboratories|2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives|
    US5837829A|1996-04-02|1998-11-17|Abbott Laboratories|9-oximesilyl erythromycin a derivatives|
    US5858986A|1996-07-29|1999-01-12|Abbott Laboratories|Crystal form I of clarithromycin|
    KR100524214B1|1996-07-29|2005-11-01|아보트 러보러터리즈|Preparation of crystal form II of clarithromycin|
    AU777612B2|1996-07-29|2004-10-21|Bgp Products Operations Gmbh|Crystal form I of clarithromycin|
    US5945405A|1997-01-17|1999-08-31|Abbott Laboratories|Crystal form O of clarithromycin|
    US5864023A|1997-02-13|1999-01-26|Abbott Laboratories|3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives|
    US5929219A|1997-09-10|1999-07-27|Abbott Laboratories|9-hydrazone and 9-azine erythromycin derivatives and a process of making the same|
    US5852180A|1997-11-17|1998-12-22|Abbott Laboratories|Chemical synthesis of 6-O-alkyl erythromycin A|
    US5932710A|1997-12-01|1999-08-03|Abbott Laboratories|Process for preparing 6-O-alkyl-9-oxime erythromycin B|
    IL135792D0|1997-12-01|2001-05-20|Abbott Lab|6-o-alkyl derivatives of erythronolide b|
    US5892008A|1997-12-16|1999-04-06|Abbott Laboratories|Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives|
    IL124084D0|1998-04-14|1999-04-11|Chemagis Ltd|Erythromycin a derivatives and methods for the preparation thereof|
    IL125372D0|1998-07-15|1999-03-12|Chemagis Ltd|Erythromycin derivatives and methods for the preparation thereof|
    CA2411293A1|1999-01-28|2000-07-28|Pfizer Products Inc.|Novel azalides and methods of making same|
    US6420535B1|1999-06-07|2002-07-16|Abbott Laboratories|6-O-carbamate ketolide derivatives|
    US6437106B1|1999-06-24|2002-08-20|Abbott Laboratories|Process for preparing 6-o-substituted erythromycin derivatives|
    KR20010008496A|1999-07-01|2001-02-05|유충식|Process for the preparation of 6-O-methyl erythromycin|
    US6569836B2|1999-12-02|2003-05-27|Abbott Laboratories|6-O-alkyl-2-nor-2-substituted ketolide derivatives|
    US6627743B1|1999-12-03|2003-09-30|Abbott Laboratories|6-O-methylerythromycin A crystal form III|
    PT1254146E|1999-12-16|2005-10-31|Teva Pharma|CLARITROMYCINE POLYMER PREPARATION PROCESSES AND NEW POLYMORPH IV|
    DK1280535T3|2000-01-11|2005-04-04|Teva Pharma|Processes for the preparation of clarithromycin polymorphs|
    US6544555B2|2000-02-24|2003-04-08|Advancis Pharmaceutical Corp.|Antibiotic product, use and formulation thereof|
    US6565882B2|2000-02-24|2003-05-20|Advancis Pharmaceutical Corp|Antibiotic composition with inhibitor|
    US6946446B2|2000-02-24|2005-09-20|Abbott Laboratories|Anti-infective agents useful against multidrug-resistant strains of bacteria|
    KR20030047873A|2000-02-29|2003-06-18|테바 파마슈티컬 인더스트리즈 리미티드|Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same|
    ES2242668T3|2000-03-15|2005-11-16|Hanmi Pharm. Co., Ltd.|METHOD FOR OBTAINING CLARITROMYCIN IN CRYSTALS OF FORM II.|
    US6605707B1|2000-03-23|2003-08-12|Abbott Laboratories|Process for the preparation of 6-O-propargyl erythromycin derivatives|
    EP1283821B1|2000-05-15|2004-03-03|Ranbaxy Laboratories, Ltd.|A cost effective method for selective methylation of erythromycin a derivatives|
    US20020068078A1|2000-10-13|2002-06-06|Rudnic Edward M.|Antifungal product, use and formulation thereof|
    US6541014B2|2000-10-13|2003-04-01|Advancis Pharmaceutical Corp.|Antiviral product, use and formulation thereof|
    KR100367981B1|2000-11-23|2003-01-14|한미약품공업 주식회사|Process for preparing form ii crystals of clarithromycin and crystalline clarithromycin mesilate trihydrate used therein|
    US6843854B2|2002-05-31|2005-01-18|Purdue Research Foundation|Method and apparatus for separating a component from a mixture|
    WO2005009368A2|2003-07-21|2005-02-03|Advancis Pharmaceutical Corporation|Antibiotic product, use and formulation thereof|
    JP2006528185A|2003-07-21|2006-12-14|アドバンシスファーマスーティカルコーポレイション|Antibiotic preparations, their use and preparation|
    EP1648415A4|2003-07-21|2011-11-16|Middlebrook Pharmaceuticals Inc|Antibiotic product, use and formulation thereof|
    US8758820B2|2003-08-11|2014-06-24|Shionogi Inc.|Robust pellet|
    US8062672B2|2003-08-12|2011-11-22|Shionogi Inc.|Antibiotic product, use and formulation thereof|
    US7407941B2|2003-08-26|2008-08-05|Pfizer, Inc.|N-desmethyl-N-substituted-11-deoxyerythromycin compounds|
    CA2535780A1|2003-08-29|2005-03-17|Advancis Pharmaceuticals Corporation|Antibiotic product, use and formulation thereof|
    JP2007513869A|2003-09-15|2007-05-31|アドバンシスファーマスーティカルコーポレイション|Antibiotic preparations, their use and preparation|
    AU2005269981A1|2004-07-02|2006-02-09|Bonck, John A|Tablet for pulsed delivery|
    US20060111560A1|2004-11-01|2006-05-25|Glenmark Pharmaceuticals Limited|Process for the preparation of crystalline form II of clarithromycin|
    WO2006064299A1|2004-12-13|2006-06-22|Wockhardt Limited|Industrial process of clarithromycin associated with controlled level of side products|
    US8357394B2|2005-12-08|2013-01-22|Shionogi Inc.|Compositions and methods for improved efficacy of penicillin-type antibiotics|
    US8299052B2|2006-05-05|2012-10-30|Shionogi Inc.|Pharmaceutical compositions and methods for improved bacterial eradication|
    US8778924B2|2006-12-04|2014-07-15|Shionogi Inc.|Modified release amoxicillin products|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    JP5361885|1985-03-18|
    JP20935785|1985-09-21|
    [返回顶部]